The main research objective of dIscOverNET is moving the needle for advanced immune-driven strategies in NET from concept to ready for clinical validation.
With this objective in mind, uniquely, a clinic-to-lab-to-clinic model will be used, as the dIscOverNET doctoral network brings together leading academic institutions, clinical centers as well as patient representatives, and industrial partners. With complementary expertise spanning tumor immunology, cell therapy, spatial biology, therapeutic development, preclinical modeling, and clinical translation, they will be working together to advance the field of immunotherapy in NET beyond the current state-of-the-art in other cancer types.
We hypothesize that immunotherapy efficacy in NET can be unlocked by developing therapeutic approaches tailored to the unique features of NET, integrating these with tumor-priming strategies through modulation of the tumor immune microenvironment (TIME), and evaluating them in advanced experimental NET models that more faithfully recapitulate physiologically relevant TIME interactions.
This highly innovative scientific work will be executed in three distinct but complementary scientific Work Packages that will tackle six research objectives:
Work Package 4: Accelerate
The goal is to accelerate the rational design and implementation of immune-driven therapies that are tailored to the unique biology of NET. We aim to achieve this by redefining target identification strategies through applying 3 complementary approaches to discover novel NET-specific (immunogenic) targets by creating target/epitope prioritization pipelines, by developing 3 novel NET-specific immuno-oncology strategies using validated targets and demonstrating therapeutic efficacy of these (novel) immuno-oncology strategies in NET.
Work Package 5: Demonstrate
This second research work package aims to demonstrate the potential of prime–to-boost strategies using tumor–immune microenvironment (TIME) modulation via in-depth TIME mapping using complementary advanced immunohistochemistry (IHC) and sequencing-based methods, use this data to discover novel, clinically actionable strategies for TIME modulation and provide proof-of-concept for 4 strategies to prime NET by reversing the immuno-cold signature.
Work Package 6: Develop
Finally, we wish to develop and validate advanced complementary preclinical platforms capable of addressing immune-driven therapeutic questions by integrating a harmonized collection of fresh NET tumor tissue and establish 3 novel in vitro approaches that accurately reproduce tumor–TIME interactions to facilitate medium-throughput screening and functional assays as well as 2 in vivo models allowing efficacy testing of novel immune-driven strategies.